Not Yet RecruitingPhase 4ACTRN12611000603910

Does scopolamine improve attention more than placebo in healthy volunteers and what does this tell us about mechanisms of attention?

Does scopolamine improve selective attention and cognition more than placebo in healthy male volunteers?


Sponsor

The University of Queensland

Enrollment

25 participants

Start Date

Jun 20, 2011

Study Type

Interventional

Conditions

Summary

Attentional processing is a cognitive skill that allows us to interpret and act in our environment. Although this skill is important, little is understoond about the neurochemical processes that are important to attention. This study will allow us to assess the importance of different brain chemicals in contributing to selective attention function.


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 40 Yearss

Inclusion Criteria3

  • Healthy volunteers
  • Aged 18-40 years
  • Male

Exclusion Criteria4

  • Current psychiatric or neurological diagnosis
  • Current use of psychotropic medication
  • Current use of cholinergic or anticholinergic medication
  • Medical condition in which scopolamine is contraindicated

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A single dose of scopolamine (0.8mg contained in one capsule) (1-2 week washout between conditions)

A single dose of scopolamine (0.8mg contained in one capsule) (1-2 week washout between conditions)


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000603910